Molecular Partners AG (XSWX:MOLN) Short Percentage of Float


XSWX:MOLN Molecular Partners AG XSWX:MOLN
27 GF Score
Price CHF3.18
GF Value CHF0.37
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XSWX:MOLN vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Molecular Partners AG's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Short Percentage of Float falls into.


XSWX:MOLN
27GF Score
Molecular Partners AG XSWX:MOLN
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of CHF3.18 is trading 759.5% above its estimated GF Value™ of CHF0.37. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for XSWX:MOLN:

  • Short Percentage of Float:
  • GF Value™: CHF0.37 vs. price of CHF3.18 (759.5% above fair value)
  • GF Score™: 27/100 with 3 warning signs

No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
27GF Score

Get the complete analysis for XSWX:MOLN

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.18
Price
CHF0.37
GF Value